Aiming at
tumor targeting delivery of
oxaliplatin using
polymer therapy, a new monomeric
platinum(II) complex (
dach)Pt[HEDM] (
dach: trans-(±)-1,2-diaminocyclohexane; HEDM: 2-hydroxyethoxydiethylmalate) was designed to include the antitumor moiety (
dach)Pt and HEDM as a linker to the
polyphosphazene backbone. This monomeric Pt-complex could easily be grafted to the PEGylated
polyphosphazene backbone to prepare a novel
polyphosphazene-Pt conjugate, [NP(MPEG550)(
dach)Pt(EM)]n [MPEG550: methoxy poly(
ethylene glycol) with an average molecular weight of 550; EM: ethoxymalate]. This amphiphilic
polyphosphazene-Pt conjugate was found to self-assemble into stable polymeric
micelles of a mean diameter of 130nm, which is suitable for passive
tumor targeting by enhanced permeability and retention (EPR) effect. Pharmacokinetic study of this
polymer conjugate exhibited long blood circulation as expected and longer half-life (t1/2β=9.52h) compared with
oxaliplatin (3.47h), and much larger AUC (area under the curve) value (25,831ng·h/mL) compared with
oxaliplatin (1194ng·h/mL). Biodistribution study of the
polymer conjugate has shown excellent
tumor selectivity with the
tumor to tissue ratio of 3.84 at 2h post injection and 11.7 at 24h post injection probably due to the EPR effect of the
polymer conjugate while no
tumor selectivity was observed for monomeric
oxaliplatin. Furthermore, accumulation of this
polymer conjugate in kidney was much lower compared with
oxaliplatin. Also the nude mouse xenograft trial of the
polymer conjugate has shown higher antitumor efficacy compared with
oxaliplatin.